Polyethylene Glycol 400
GET
/api/v1/drug/polyethylene-glycol-400Mechanism of action
Sourced from openFDAMechanism-of-action class: Demulcent Activity.
Indications
Sourced from openFDA- Uses for protection against further irritation for temporary relief of burning and irritation due to dryness of the eye
Dosage & administration
Sourced from openFDADirections instill 1 to 2 drops in the affected eye(s) as needed
Warnings & precautions
Sourced from openFDAFor external use only Do not use this product if solution changes color or becomes cloudy When using this product to avoid contamination, do not touch tip of container to any surface. Replace cap after using. remove contact lenses before using Stop use and ask a doctor if you experience eye pain changes in vision continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center (1-800-222-1222) right away.
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
16,042 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Drug Ineffective2,18314%
- 2Off Label Use1,3318.3%
- 3Incorrect Product Administration Duration1,2687.9%
- 4Eye Irritation1,0186.3%
- 5Nausea9956.2%
- 6Diarrhoea9355.8%
- 7Constipation7224.5%
- 8Vision Blurred7174.5%
- 9Headache6584.1%
- 10Vomiting6504.1%
- 11Incorrect Drug Administration Duration6283.9%
- 12Abdominal Pain6123.8%
- 13Fatigue6123.8%
- 14Underdose6023.8%
- 15Eye Pain5363.3%
Clinical trials
The 10 most recently updated of 794 ClinicalTrials.gov registrations naming Polyethylene Glycol 400 as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Recruiting · Phase 2 · Interventional · 461 enrolled · National Cancer Institute (NCI)NCT04546399updated 2026-06-12
- Biological, Radiographic and Clinical Evaluation of Various Inter-Visit Root Canal Dressings in Retreatment CasesRecruiting · Phase 1 · Interventional · 60 enrolled · Ain Shams UniversityNCT07641933updated 2026-06-12
- Faecal Microbiota Transplantation After Allogeneic Stem Cell TransplantationRecruiting · Phase 2 · Interventional · 150 enrolled · University Hospital, Clermont-FerrandNCT04935684updated 2026-06-09
- Effect of Metformin, a Drug Used to Treat Diabetes, vs PlaceboActive not recruiting · Phase 4 · Interventional · 150 enrolled · University of California, Los AngelesNCT05949008updated 2026-06-08
- Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaRecruiting · Phase 2 · Interventional · 80 enrolled · Children's Oncology GroupNCT02981628updated 2026-06-05
- Fecal Microbiota Transplantation for Elderly Patients With HFpEF: A Randomized Controlled TrialNot yet recruiting · Phase 1 · Phase 2 · Interventional · 50 enrolled · The First Affiliated Hospital of Air Force Medicial UniversityNCT07628777updated 2026-06-05
- PET [89Zr]DFO-starPEG in Solid TumorsRecruiting · Phase 1 · Interventional · 13 enrolled · Robert Flavell, MD, PhDNCT06894745updated 2026-06-05
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)Recruiting · Phase 2 · Interventional · 222 enrolled · National Cancer Institute (NCI)NCT06124157updated 2026-06-03
- Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic LymphomaActive not recruiting · Phase 3 · Interventional · 847 enrolled · National Cancer Institute (NCI)NCT02112916updated 2026-06-03
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaActive not recruiting · Phase 3 · Interventional · 669 enrolled · National Cancer Institute (NCI)NCT02101853updated 2026-06-03
Frequently asked questions
- How does Polyethylene Glycol 400 work?
- Mechanism-of-action class: Demulcent Activity.
- What is Polyethylene Glycol 400 used for?
- According to FDA labeling, Polyethylene Glycol 400 carries indications including: Uses for protection against further irritation for temporary relief of burning and irritation due to dryness of the eye. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
- What class of drug is Polyethylene Glycol 400?
- Polyethylene Glycol 400 is classified as Demulcent Activity.
- What are the brand names for Polyethylene Glycol 400?
- Polyethylene Glycol 400 is marketed under brand names including Blink Tears, Ocusan Dry Eyes.
Note. Data for
polyethylene-glycol-400 is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.